Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Breast Cancer

Free Subscription 01.01.2020 1 Am J Clin Oncol 1 Am J Pathol 1 Am J Surg 3 Ann Oncol 5 Ann Surg Oncol 1 Anticancer Res 8 BMC Cancer 1 Breast Cancer 7 Breast Cancer Res 8 Breast Cancer Res Treat 12 Breast J 4 Cancer 2 Cancer Chemother Pharmacol 4 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 1 Cancer Res 1 Clin Breast Cancer 3 Clin Cancer Res 1 Eur J Surg Oncol 1 Gene 2 Histopathology 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 2 J Clin Oncol 2 J Natl Cancer Inst 1 J Nucl Med 1 J Surg Oncol 1 JAMA 1 Lancet 3 Lancet Oncol 2 N Engl J Med 2 Nat Rev Cancer 2 Nature 1 PLoS Genet 1 PLoS Med 3 PLoS One 1 Proc Natl Acad Sci U S A 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. GOLD HT, Shao H, Oratz R, Yu O, et al
   Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer.
   Am J Clin Oncol. 2019 Dec 16. doi: 10.1097/COC.0000000000000638.
   PubMed     Text format     Abstract available
   
   

   
   Am J Pathol

2. LOPEZ C, Bosch R, Orero G, Korzynska A, et al
   The immune response in non-metastatic axillary lymph nodes is associated with the presence of axillary metastasis and breast cancer patient outcome.
   Am J Pathol. 2019 Dec 19. pii: S0002-9440(19)30860.
   PubMed     Text format     Abstract available
   
   

   
   Am J Surg

3. AGBORBESONG O, Helmer SD, Reyes J, Strader LA, et al
   Breast cancer treatment in the elderly: Do treatment plans that do not conform to NCCN recommendations lead to worse outcomes?
   Am J Surg. 2019 Dec 5. pii: S0002-9610(19)31558.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

4. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
   Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
   Ann Oncol. 2019;30.
   PubMed     Text format     Abstract available
   
   
5. VASAN N, Toska E, Scaltriti M
   Overview of the relevance of PI3K pathway in HR-positive breast cancer.
   Ann Oncol. 2019;30.
   PubMed     Text format     Abstract available
   
   
6. VERRET B, Cortes J, Bachelot T, Andre F, et al
   Efficacy of PI3K inhibitors in advanced breast cancer.
   Ann Oncol. 2019;30.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

7. HANNOUN-LEVI JM, Hannoun A
   Downs-Canner S, Zabor EC, Wind T, Cobovic A, McCormick B, Morrow M, Heerdt A-Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose? In Regard to Downs-Canner et al.
   Ann Surg Oncol. 2019;26.
   PubMed     Text format    
   
   
8. DOWNS-CANNER S, Heerdt A
   Reply to "Downs-Canner S, Zabor EC, Wind T, Cobovic A, McCormick B, Morrow M, Heerdt A. Radiation Therapy After Breast-Conserving Surgery for Women 70 Years of Age or Older: How Wisely Do We Choose? In Regard to Downs-Canner et al." by Hannoun-Levi, J
   Ann Surg Oncol. 2019;26.
   PubMed     Text format    
   
   
9. FISHER CS, Margenthaler JA, Hunt KK, Schwartz T, et al
   The Landmark Series: Axillary Management in Breast Cancer.
   Ann Surg Oncol. 2019 Dec 20. pii: 10.1245/s10434-019-08154.
   PubMed     Text format     Abstract available
   
   
10. WIMMER K, Bolliger M, Bago-Horvath Z, Steger G, et al
    Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival.
    Ann Surg Oncol. 2019 Dec 23. pii: 10.1245/s10434-019-08089.
    PubMed     Text format     Abstract available
    
    
11. VALERO MG, King TA, Pilewskie ML
    ASO Author Reflections: Breast Cancer Risk Assessment in Women with LCIS-More Work Is Needed.
    Ann Surg Oncol. 2019 Dec 20. pii: 10.1245/s10434-019-07936.
    PubMed     Text format    
    
    

    
    Anticancer Res

12. BOCZAR D, Restrepo DJ, Sisti A, Huayllani MT, et al
    Influence of Facility Characteristics on Access to Breast Reconstruction: A 12-Year National Cancer Database Analysis.
    Anticancer Res. 2019;39:6881-6885.
    PubMed     Text format     Abstract available
    
    

    
    BMC Cancer

13. CAMACHO F, Anderson R, Kimmick G
    Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia.
    BMC Cancer. 2019;19:1228.
    PubMed     Text format     Abstract available
    
    
14. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Text format     Abstract available
    
    
15. VRINTEN C, Gallagher A, Waller J, Marlow LAV, et al
    Cancer stigma and cancer screening attendance: a population based survey in England.
    BMC Cancer. 2019;19:566.
    PubMed     Text format     Abstract available
    
    
16. KAREDATH T, Ahmed I, Al Ameri W, Al-Dasim FM, et al
    Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes.
    BMC Cancer. 2019;19:565.
    PubMed     Text format     Abstract available
    
    
17. KIZILBOGA T, Baskale EA, Yildiz J, Akcay IM, et al
    Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer.
    BMC Cancer. 2019;19:1254.
    PubMed     Text format     Abstract available
    
    
18. HOSHINA H, Takei H
    Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:1217.
    PubMed     Text format     Abstract available
    
    
19. RESENDE U, Cabello C, Ramalho SOB, Zeferino LC, et al
    Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    BMC Cancer. 2019;19:601.
    PubMed     Text format     Abstract available
    
    
20. TORDJMAN J, Majumder M, Amiri M, Hasan A, et al
    Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
    BMC Cancer. 2019;19:561.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer

21. LIAO W, Huang J, Wu Q, Wen F, et al
    First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
    Breast Cancer. 2019 Dec 18. pii: 10.1007/s12282-019-01034.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

22. GIARDIELLO D, Steyerberg EW, Hauptmann M, Adank MA, et al
    Prediction and clinical utility of a contralateral breast cancer risk model.
    Breast Cancer Res. 2019;21:144.
    PubMed     Text format     Abstract available
    
    
23. SNODERLY HT, Boone BA, Bennewitz MF
    Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment.
    Breast Cancer Res. 2019;21:145.
    PubMed     Text format     Abstract available
    
    
24. WAN L, Liu T, Hong Z, Pan Y, et al
    NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Breast Cancer Res. 2019;21:148.
    PubMed     Text format     Abstract available
    
    
25. FERNANDEZ-GARCIA D, Hills A, Page K, Hastings RK, et al
    Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
    Breast Cancer Res. 2019;21:149.
    PubMed     Text format     Abstract available
    
    
26. LI CH, Karantza V, Aktan G, Lala M, et al
    Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Breast Cancer Res. 2019;21:143.
    PubMed     Text format     Abstract available
    
    
27. NEDERLOF I, De Bortoli D, Bareche Y, Nguyen B, et al
    Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
    Breast Cancer Res. 2019;21:151.
    PubMed     Text format     Abstract available
    
    
28. PATEL HK, Tao N, Lee KM, Huerta M, et al
    Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Breast Cancer Res. 2019;21:146.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

29. CHEN HL, Du L, Li XM
    Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 19. pii: 10.1007/s10549-019-05510.
    PubMed     Text format    
    
    
30. LI Y, Zhou Y, Mao F, Lin Y, et al
    Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Breast Cancer Res Treat. 2019 Dec 21. pii: 10.1007/s10549-019-05513.
    PubMed     Text format     Abstract available
    
    
31. MALTONI R, Bravaccini S
    What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
    Breast Cancer Res Treat. 2019;177:231-232.
    PubMed     Text format    
    
    
32. ANGARITA FA, Dossa F, Zuckerman J, McCready DR, et al
    Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2019;177:215-224.
    PubMed     Text format     Abstract available
    
    
33. HELLAND T, Hagen KB, Haugstoyl ME, Kvaloy JT, et al
    Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.
    Breast Cancer Res Treat. 2019;177:185-195.
    PubMed     Text format     Abstract available
    
    
34. MARMOR S, Altman AM, Mayleben WT, Hui JYC, et al
    The use of contralateral prophylactic mastectomy among elderly patients in the United States.
    Breast Cancer Res Treat. 2019;177:175-183.
    PubMed     Text format     Abstract available
    
    
35. ALTUNDAG K
    ER(+)/HER2(+) and ER-/HER2(+) breast cancers might have different intracranial recurrence patterns after brain-directed radiation for brain metastases.
    Breast Cancer Res Treat. 2019;177:233.
    PubMed     Text format    
    
    
36. CHEN XY, Yeong J, Thike AA, Bay BH, et al
    Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Breast Cancer Res Treat. 2019;177:17-27.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

37. GIULIANO AE
    The evolution of sentinel node biopsy for breast cancer: Personal experience.
    Breast J. 2019 Dec 26. doi: 10.1111/tbj.13729.
    PubMed     Text format     Abstract available
    
    
38. WONG RX, Kusumawidjaja G, Tan V
    Solitary contralateral axillary metastasis in breast cancer: Is it a true distant spread?
    Breast J. 2019 Dec 26. doi: 10.1111/tbj.13733.
    PubMed     Text format    
    
    
39. OHRI N, Haffty BG
    The evolution of adjuvant radiation therapy for early-stage and locally advanced breast cancer.
    Breast J. 2019 Dec 19. doi: 10.1111/tbj.13715.
    PubMed     Text format     Abstract available
    
    
40. PETRILLO A, Fusco R, Vallone P, Filice S, et al
    Digital breast tomosynthesis and contrast-enhanced dual-energy digital mammography alone and in combination compared to 2D digital synthetized mammography and MR imaging in breast cancer detection and classification.
    Breast J. 2019 Dec 30. doi: 10.1111/tbj.13739.
    PubMed     Text format     Abstract available
    
    
41. HUGHES KS, Zhou J, Bao Y, Singh P, et al
    Natural language processing to facilitate breast cancer research and management.
    Breast J. 2019 Dec 18. doi: 10.1111/tbj.13718.
    PubMed     Text format     Abstract available
    
    
42. BRUFSKY A, Mathew A
    Adjuvant bisphosphonate therapy in early-stage breast cancer-Treating the soil to kill the seed.
    Breast J. 2019 Dec 26. doi: 10.1111/tbj.13730.
    PubMed     Text format     Abstract available
    
    
43. DJOHAN R, Knackstedt R
    Collaboration between breast and reconstructive surgery in optimizing outcomes for women with breast cancer.
    Breast J. 2019 Dec 26. doi: 10.1111/tbj.13723.
    PubMed     Text format     Abstract available
    
    
44. MELNIK I, Yerushalmi R, Sobol Y, Magen A, et al
    Intraoperative radiation therapy for breast cancer-Immediate and 30-month oncological outcomes.
    Breast J. 2019 Dec 26. doi: 10.1111/tbj.13708.
    PubMed     Text format     Abstract available
    
    
45. HILAL T, Mi L, Ertz-Archambault NM, Almquist DR, et al
    Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer.
    Breast J. 2019 Dec 26. doi: 10.1111/tbj.13731.
    PubMed     Text format    
    
    
46. AZIM HA, Ghosn M, Oualla K, Kassem L, et al
    Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
    Breast J. 2019 Dec 23. doi: 10.1111/tbj.13713.
    PubMed     Text format     Abstract available
    
    
47. CARLSON GW
    The changing surgical treatment of breast cancer in the United States: The tipping point.
    Breast J. 2019 Dec 22. doi: 10.1111/tbj.13725.
    PubMed     Text format     Abstract available
    
    
48. DIXON JM, Cartlidge CWJ
    Twenty-five years of change in the management of the axilla in breast cancer.
    Breast J. 2019 Dec 19. doi: 10.1111/tbj.13720.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

49. MANDELBLATT JS, Zhai W, Ahn J, Small BJ, et al
    Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32663.
    PubMed     Text format     Abstract available
    
    
50. ROBERTS AW, Fergestrom N, Neuner JM, Winn AN, et al
    New-onset persistent opioid use following breast cancer treatment in older adult women.
    Cancer. 2019 Dec 17. doi: 10.1002/cncr.32593.
    PubMed     Text format     Abstract available
    
    
51. DOWNS-CANNER SM, Gaber CE, Louie RJ, Strassle PD, et al
    Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32668.
    PubMed     Text format     Abstract available
    
    
52. PAPAKONSTANTINOU A, Matikas A, Bengtsson NO, Malmstrom P, et al
    Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial.
    Cancer. 2019 Dec 18. doi: 10.1002/cncr.32653.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

53. ZHAO Y, Wei L, Liu J, Li F, et al
    Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
    Cancer Chemother Pharmacol. 2019 Dec 16. pii: 10.1007/s00280-019-04009.
    PubMed     Text format     Abstract available
    
    
54. PATTARAWAT P, Wallace S, Pfisterer B, Odoi A, et al
    Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Cancer Chemother Pharmacol. 2019 Dec 21. pii: 10.1007/s00280-019-04013.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

55. WANG F, Cai H, Gu K, Shi L, et al
    Adherence to Dietary Recommendations Among Long-Term Breast Cancer Survivors and Cancer Outcome Associations.
    Cancer Epidemiol Biomarkers Prev. 2019 Dec 23. pii: 1055-9965.EPI-19-0872.
    PubMed     Text format     Abstract available
    
    
56. HSU CD, Peacock Hinton S, Reeder-Hayes KE, Sanoff HK, et al
    Association between concomitant use of hydrochlorothiazide and adverse chemotherapy-related events among older women with breast cancer treated with cyclophosphamide.
    Cancer Epidemiol Biomarkers Prev. 2019 Dec 23. pii: 1055-9965.EPI-19-1079.
    PubMed     Text format     Abstract available
    
    
57. ADEDOKUN B, Zheng Y, Ndom P, Gakwaya A, et al
    Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Uganda and Cameroon Women.
    Cancer Epidemiol Biomarkers Prev. 2019 Dec 23. pii: 1055-9965.EPI-19-0506.
    PubMed     Text format     Abstract available
    
    
58. CHENG TD, Yao S, Omilian AR, Khoury T, et al
    FOXA1 protein expression in ER+ and ER- breast cancer in relation to parity and breastfeeding in Black and White women.
    Cancer Epidemiol Biomarkers Prev. 2019 Dec 23. pii: 1055-9965.EPI-19-0787.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

59. SAND A, Piacsek M, Donohoe DL, Duffin AT, et al
    WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
    Cancer Lett. 2019;472:119-131.
    PubMed     Text format     Abstract available
    
    
60. SI P, Shi J, Zhang P, Wang C, et al
    MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer.
    Cancer Lett. 2019 Dec 16. pii: S0304-3835(19)30625.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

61. CITRON F, Segatto I, Rampioni Vinciguerra GL, Musco L, et al
    Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer.
    Cancer Res. 2019 Dec 20. pii: 0008-5472.CAN-19-1793.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

62. BROWN CL, McEvoy MP, Smith BL, Lanahan CR, et al
    Long-Term Outcomes of Multiple-Wire Localizations for More Extensive Breast Cancer: Multiple-Wire Excision Does Not Increase Recurrence, Unplanned Imaging, or Biopsies.
    Clin Breast Cancer. 2019 Nov 23. pii: S1526-8209(19)30737.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

63. CHEN G, Ding X, Pressley K, Bouamar H, et al
    Everolimus inhibits the progression of ductal carcinoma in situ to invasive breast cancer via downregulation of MMP9 expression.
    Clin Cancer Res. 2019 Dec 23. pii: 1078-0432.CCR-19-2478.
    PubMed     Text format     Abstract available
    
    
64. LIU S, Gonzalez Prieto R, Zhang M, Geurink PP, et al
    Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFbeta-induced breast cancer metastasis.
    Clin Cancer Res. 2019 Dec 19. pii: 1078-0432.CCR-19-1373.
    PubMed     Text format     Abstract available
    
    
65. LI Q, Wang Y, Jia W, Deng H, et al
    Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade.
    Clin Cancer Res. 2019 Dec 17. pii: 1078-0432.CCR-19-2179.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

66. BALASUBRAMIAN R, Morgan C, Shaari E, Kovacs T, et al
    Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy.
    Eur J Surg Oncol. 2019 Dec 11. pii: S0748-7983(19)31500.
    PubMed     Text format     Abstract available
    
    

    
    Gene

67. DASTMALCHI N, Safaralizadeh R, Baradaran B, Hosseinpourfeizi M, et al
    An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer.
    Gene. 2019 Dec 26:144301. doi: 10.1016/j.gene.2019.144301.
    PubMed     Text format     Abstract available
    
    

    
    Histopathology

68. ARISPE ANGULO KR, Jawa Z, Visotcky A, Majidi SS, et al
    High Mitotic Score in Breast Cancer after Neoadjuvant Chemotherapy is Predictive of Outcome and Associated with a Distinct Morphology.
    Histopathology. 2019 Dec 17. doi: 10.1111/his.14049.
    PubMed     Text format     Abstract available
    
    
69. FINSTERBUSCH K, Decker T, van Diest PJ, Focke CM, et al
    Luminal A versus B breast cancer: MammaTyper(R) mRNA versus immunohistochemical subtyping with emphasis on standardised Ki67-Labelling or Mitotic Activity Index based proliferation assessment.
    Histopathology. 2019 Dec 17. doi: 10.1111/his.14048.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

70. RAINEY L, Eriksson M, Trinh T, Czene K, et al
    The impact of alcohol consumption and physical activity on breast cancer: the role of breast cancer risk.
    Int J Cancer. 2019 Dec 21. doi: 10.1002/ijc.32846.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

71. WRIGHT JL, Bellon JR
    Defining the Optimal Schedule for External Beam Partial Breast Irradiation.
    Int J Radiat Oncol Biol Phys. 2019;104:867-868.
    PubMed     Text format    
    
    

    
    J Clin Oncol

72. HAYES DF, Rae JM
    Pharmacogenomics and Endocrine Therapy in Breast Cancer.
    J Clin Oncol. 2019 Dec 27:JCO1903119. doi: 10.1200/JCO.19.03119.
    PubMed     Text format    
    
    
73. AMBROSONE CB, Zirpoli GR, Hutson AD, McCann WE, et al
    Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
    J Clin Oncol. 2019 Dec 19:JCO1901203. doi: 10.1200/JCO.19.01203.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

74. SEBUODEGARD S, Botteri E, Hofvind S
    Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway.
    J Natl Cancer Inst. 2019 Dec 17. pii: 5678884. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
75. TERAS LR, Patel AV, Wang M, Yaun SS, et al
    Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2019 Dec 13. pii: 5675519. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Nucl Med

76. HERNANDEZ R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, et al
    (177)Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.236265. doi: 10.2967/jnumed.119.236265.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

77. KANDA MH, da Costa Vieira RA, Lima JPSN, Paiva CE, et al
    Late locoregional complications associated with adjuvant radiotherapy in the treatment of breast cancer: Systematic review and meta-analysis.
    J Surg Oncol. 2019 Dec 26. doi: 10.1002/jso.25820.
    PubMed     Text format     Abstract available
    
    

    
    JAMA

78. FAYANJU OLM
    Hiding in Plain Sight.
    JAMA. 2019;322:2173-2174.
    PubMed     Text format    
    
    

    
    Lancet

79. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.
    PubMed     Text format    
    
    

    
    Lancet Oncol

80. GAO JJ, Cheng J, Bloomquist E, Sanchez J, et al
    CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30804.
    PubMed     Text format     Abstract available
    
    
81. CURIGLIANO G, Loibl S
    CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30808.
    PubMed     Text format    
    
    
82. GOURD K
    San Antonio Breast Cancer Symposium 2019.
    Lancet Oncol. 2019 Dec 19. pii: S1470-2045(19)30830.
    PubMed     Text format    
    
    

    
    N Engl J Med

83. 
    Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2019 Dec 27. doi: 10.1056/NEJMx190039.
    PubMed     Text format    
    
    
84. BAKKER MF, de Lange SV, Pijnappel RM, Mann RM, et al
    Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.
    N Engl J Med. 2019;381:2091-2102.
    PubMed     Text format     Abstract available
    
    

    
    Nat Rev Cancer

85. KELLER L, Pantel K
    Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells.
    Nat Rev Cancer. 2019;19:553-567.
    PubMed     Text format     Abstract available
    
    
86. ZAHNOW CA
    When the cancer researcher becomes the patient.
    Nat Rev Cancer. 2019;19:603-604.
    PubMed     Text format    
    
    

    
    Nature

87. MARABELLI M, Calvello M, Bonanni B
    Cancer: more genetic BRCA testing for men.
    Nature. 2019;573:346.
    PubMed     Text format    
    
    
88. GOMIS RR
    Survival skills ensure that cancer spreads.
    Nature. 2019;573:353-354.
    PubMed     Text format    
    
    

    
    PLoS Genet

89. GUARISCHI-SOUSA R, Monteiro JS, Alecrim LC, Michaloski JS, et al
    A transcriptome-based signature of pathological angiogenesis predicts breast cancer patient survival.
    PLoS Genet. 2019;15:e1008482.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Med

90. KABORE EG, Guenancia C, Vaz-Luis I, Di Meglio A, et al
    Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
    PLoS Med. 2019;16:e1002989.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

91. GIUDICI F, Petracci E, Nanni O, Bottin C, et al
    Correction: Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis.
    PLoS One. 2019;14:e0227068.
    PubMed     Text format     Abstract available
    
    
92. STARK GF, Hart GR, Nartowt BJ, Deng J, et al
    Predicting breast cancer risk using personal health data and machine learning models.
    PLoS One. 2019;14:e0226765.
    PubMed     Text format     Abstract available
    
    
93. JIANG Y, Weinberg CR, Sandler DP, Zhao S, et al
    Use of detailed family history data to improve risk prediction,with application to breast cancer screening.
    PLoS One. 2019;14:e0226407.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

94. GREENE KS, Lukey MJ, Wang X, Blank B, et al
    SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis.
    Proc Natl Acad Sci U S A. 2019 Dec 16. pii: 1911954116.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

95. BAHL M
    Harnessing the Power of Deep Learning to Assess Breast Cancer Risk.
    Radiology. 2019 Dec 17:192471. doi: 10.1148/radiol.2019192471.
    PubMed     Text format    
    
    
96. DEMBROWER K, Liu Y, Azizpour H, Eklund M, et al
    Comparison of a Deep Learning Risk Score and Standard Mammographic Density Score for Breast Cancer Risk Prediction.
    Radiology. 2019 Dec 17:190872. doi: 10.1148/radiol.2019190872.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: